Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elinzanetant - Bayer

Next Previous
X
Search
Drug Profile

Elinzanetant - Bayer

Alternative Names: BAY-3427080; GSK 1144814A; GSK-1144814; NT 814

Latest Information Update: 25 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Bayer; GlaxoSmithKline; NeRRe Therapeutics
  • Class 2 ring heterocyclic compounds; Alcohols; Amides; Antipsychotics; Drug withdrawal therapies; Fluorinated hydrocarbons; Fluorobenzenes; Oxazines; Piperazines; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vasomotor symptoms
  • Phase II Sleep disorders
  • Discontinued Opioid-related disorders; Schizophrenia

Most Recent Events

  • 25 Jun 2024 Bayer intends to submit a marketing authorisation application for elinzanetant for Vasomotor symptoms associated with menopause in 2024
  • 05 Jun 2024 Bayer intends to launch elinzanetant for the treatment of vasomotor symptoms associated with menopause
  • 16 May 2024 Pooled efficacy and adverse events from OASIS-1 and OASIS-2 phase III trial in Vasomotor symptoms released by Bayer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top